Compare MBI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | FHTX |
|---|---|---|
| Founded | 1973 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 360.5M |
| IPO Year | 1994 | 2020 |
| Metric | MBI | FHTX |
|---|---|---|
| Price | $5.16 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 498.8K | 197.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.04 | 25.32 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,000,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 90.48 | 36.75 |
| 52 Week Low | $4.84 | $3.27 |
| 52 Week High | $8.26 | $6.95 |
| Indicator | MBI | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.84 | 62.08 |
| Support Level | N/A | $4.43 |
| Resistance Level | $6.26 | $6.76 |
| Average True Range (ATR) | 0.19 | 0.44 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 49.95 | 72.18 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. The U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiaries.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.